Vertex’s goal over much of the past decade has been on treating cystic fibrosis, targeting the dysfunctional CFTR chloride channel at the root of the disease. Following the speedy approval in October of its triple combination therapy Trikafta, nearly 90% of people with cystic fibrosis now stand to benefit from the firm’s CFTR potentiators and correctors. With this landmark success in hand — and the lucrative market it has opened up — the company is now in the process of broadening its horizons. In April 2020, current CMO Reshma Kewalramani will step up to the CEO role to oversee the transition. She spoke with Asher Mullard about the lessons the company has learned from cystic fibrosis drug development and its future R&D plans.

中文翻译：

---

Reshma Kewalramani。

在过去十年的大部分时间里，Vertex的目标一直是治疗囊性纤维化，将功能失常的CFTR氯化物通道靶向到疾病的根源。在十月份三联疗法Trikafta迅速获得批准后，囊性纤维化患者中近90％的人现在将从该公司的CFTR增强剂和校正剂中受益。有了这一具有里程碑意义的成功-并开拓了有利可图的市场-该公司现在正在扩大视野。2020年4月，现任CMO Reshma Kewalramani将担任首席执行官一职，以监督这一转变。她与艾舍尔·穆拉德（Asher Mullard）谈了公司从囊性纤维化药物开发及其未来研发计划中吸取的教训。